MR CLEAN LATE
Endovascular Treatment of Acute Stroke for Late arri
This website provides information about the MR CLEAN LATE trial, a multicenter randomized clinical performed within the CONTRAST consortium. The goal is to assess the effect of endovascular treatment, compared with best medical treatment, in patients with acute ischemic stroke presenting between 6 and 24 hours after onset (or last seen well) caused by an intracranial large vessel occlusion of the anterior circulation.
The left hand menu helps you to navigate through this website and access more information about the trial.
Final patient included in the MR CLEAN LATE
On the 27th of January 2022, the final patient (with registered consent) was included in the MR CLEAN LATE trial.
Results of the MR CLEAN-LATE trial have been published in the Lancet in April 2023: https://www.nejm.org/doi/full/10.1056/NEJMoa2107727.
The long-term follow-up phase of the MR CLEAN-LATE has been published in the Lancet Neurology in September 2024: https://www.sciencedirect.com/science/article/pii/S147444222400228X?via%3Dihub
Kind regards,
MR CLEAN LATE principal investigators on behalf of the CONTRAST consortium.
Robert van Oostenbrugge and Wim van Zwam
Maastricht University Medical Center, Maastricht